⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Sinedore Holdings Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Sinedore Holdings Ltd.
↗Taipei, Taiwan
Sinedore is a biotechnology company dedicated to revolutionizing drug delivery through needle-free, patient-centric technologies. The company focuses on replacing traditional injectable therapies with sublingual, intranasal, and transdermal delivery systems to improve patient compliance, reduce medical waste, and enhance therapeutic efficacy.
Their core technology platforms—TransE™, NasoPass™, EndoEase™, and KinderDose™—leverage AI-optimized formulations and liposomal technology to deliver biologics, vaccines, and small molecules. Sinedore emphasizes sustainable, pain-free care, particularly for chronic conditions like growth hormone deficiency, diabetes, and respiratory diseases.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Seed
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical
Modalities:Biologics, Small molecule, Antibodies, Vaccines, Peptides
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Sinedore Bioscience Inc.
Key Partnerships:NVIDIA Inception Program (AI and computing support)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Jackie Yang - Business Development Director
LINKS
Website:sinedoremed.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sinedore Holdings Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.